Nurix Therapeutics (NRIX) Return on Sales (2019 - 2025)
Nurix Therapeutics (NRIX) has disclosed Return on Sales for 7 consecutive years, with 5.76% as the latest value for Q4 2025.
- On a quarterly basis, Return on Sales fell 135.0% to 5.76% in Q4 2025 year-over-year; TTM through Nov 2025 was 3.02%, a 52.0% increase, with the full-year FY2025 number at 3.15%, up 40.0% from a year prior.
- Return on Sales was 5.76% for Q4 2025 at Nurix Therapeutics, up from 7.62% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.79% in Q2 2023 to a low of 7.62% in Q3 2025.
- A 5-year average of 3.83% and a median of 3.8% in 2021 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: skyrocketed 412bps in 2023, then tumbled -373bps in 2025.
- Nurix Therapeutics' Return on Sales stood at 5.1% in 2021, then tumbled by -35bps to 6.89% in 2022, then surged by 60bps to 2.77% in 2023, then tumbled by -59bps to 4.41% in 2024, then tumbled by -31bps to 5.76% in 2025.
- Per Business Quant, the three most recent readings for NRIX's Return on Sales are 5.76% (Q4 2025), 7.62% (Q3 2025), and 0.99% (Q2 2025).